What's Happening?
DermTech Inc., a skin cancer testing company formerly headquartered in San Diego, has agreed to a settlement of up to $5 million to resolve allegations that it submitted false claims to the Medicare program. The company is accused of violating the False
Claims Act by knowingly billing Medicare for unreliable skin cancer tests. These tests reportedly had significant quality control issues. Specifically, from October 2022 to March 2023, DermTech billed Medicare for tests conducted after switching to an unvalidated positive control range for one of the key melanoma markers, making it impossible to confirm the accuracy of results. Additionally, from January 2020 to February 2022, the company billed Medicare for tests that lacked sufficient patient RNA to be properly analyzed but still generated results. Despite concerns raised about these tests, DermTech neither retracted the results nor adequately refunded Medicare. The settlement includes claims brought under the qui tam provisions of the False Claims Act by a former DermTech employee, who will receive 20% of the recovery. DermTech Inc. is currently liquidating as DTech Liquidating Inc. after filing for Chapter 11 bankruptcy in June 2024. The claims resolved do not pertain to DermTech LLC, which acquired DermTech Inc.'s assets in 2024.
Why It's Important?
This settlement underscores the critical importance of integrity and accuracy in medical diagnostic testing, particularly for serious conditions like skin cancer. The alleged actions by DermTech Inc. highlight a significant risk to patient safety, as unreliable test results could lead to misdiagnoses, delayed treatment, or unnecessary procedures, potentially impacting health outcomes. For the Medicare program, this case represents a fraudulent drain on taxpayer funds, as the government was billed for services that did not meet established quality standards. The involvement of a whistleblower, a former DermTech employee, demonstrates the vital role internal oversight and individual accountability play in uncovering and addressing healthcare fraud. This resolution also sends a clear message to other healthcare providers that the Justice Department and its partners are committed to investigating and prosecuting companies that compromise the integrity of the healthcare system for financial gain. The case reinforces the government's efforts to protect Medicare patients and ensure the delivery of reliable medical services.
What's Next?
As DermTech Inc. is currently liquidating as DTech Liquidating Inc. following its Chapter 11 bankruptcy filing, the settlement amount of up to $5 million will be processed through the bankruptcy proceedings. The United States has received an Allowed Class Three General Unsecured Claim of $5,038,011 in this process. The former DermTech employee who acted as a whistleblower will receive 20% of the recovery from the bankruptcy court. This case is part of a broader initiative by the Administration, which launched the Task Force to Eliminate Fraud and the National Fraud Enforcement Division this year. These efforts aim to enhance the fight against fraud, waste, and abuse in federal programs. The Justice Department's Civil Division will continue to prioritize False Claims Act enforcement to recover funds for American taxpayers and hold wrongdoers accountable, supporting the mission of these new task forces. The resolution of this matter is expected to serve as a deterrent, encouraging other healthcare providers to adhere strictly to quality and billing standards.
Beyond the Headlines
The DermTech Inc. settlement reveals deeper implications regarding the ethical responsibilities of diagnostic companies and the regulatory oversight of medical testing. The alleged use of unvalidated control ranges and the reporting of results from insufficient samples raise serious questions about corporate governance and the internal mechanisms designed to ensure test reliability. This situation could erode public trust in diagnostic services, particularly in emerging fields like advanced skin cancer testing, where patients rely heavily on the accuracy of results for critical health decisions. The case also highlights the challenges faced by regulatory bodies in keeping pace with rapid technological advancements in medical diagnostics and ensuring that new tests meet rigorous standards before widespread adoption and reimbursement. Furthermore, the successful qui tam action underscores the importance of whistleblower protections and incentives in uncovering complex fraud schemes that might otherwise go undetected, reinforcing the idea that employees can be crucial guardians of public health and financial integrity within the healthcare system.
